KRYS
Krystal Biotech, Inc.
103.39
USD
This page is just a preview of the data found in TrendSpider’s full version
Krystal Biotech, Inc. stock is up 1.11% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 06 Dec 20:11 | 17 May, 2024 | 100.00 | 168 | ||
| 06 Dec 20:11 | 17 May, 2024 | 125.00 | 5 | ||
| 06 Dec 20:11 | 17 May, 2024 | 125.00 | 5 | ||
| 06 Dec 20:11 | 17 May, 2024 | 110.00 | 4 | ||
| 06 Dec 20:11 | 17 May, 2024 | 100.00 | 168 | ||
| 06 Dec 20:11 | 17 May, 2024 | 110.00 | 4 | ||
| 06 Dec 20:11 | 17 May, 2024 | 100.00 | 168 | ||
| 06 Dec 20:17 | 17 May, 2024 | 100.00 | 168 | ||
| 06 Dec 20:17 | 17 May, 2024 | 110.00 | 4 | ||
| 07 Dec 17:01 | 17 May, 2024 | 100.00 | 1150 |
Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.
